Zymeworks ZYME Research Milestone — Research and development collaborations (note 11)
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Zymeworks’s 10-K, filed March 2, 2026.
- Filed
- Mar 2, 2026, 6:28 AM EST
- Fiscal year
- FY2025
- Accession
- 0001937653-26-000015
The Company is eligible to receive up to $1.1 billion in milestone and other payments. From contract inception to December 31, 2025, the Company has received an upfront technology access fee payment of $6.0 million. In July 2024, the Company recognized $2.5 million of milestone revenue from GSK in relation to the sequence pair nomination by GSK under the 2016 agreement between the Company and GSK. Furthermore, in January 2025, the Company recognized $14.0 million of milestone revenue associated with a clinical milestone. As of December 31, 2025, the Company is also eligible to receive research milestone payments of up to $35.0 million, development milestone payments of up to $168.5 million and commercial milestone payments of up to $867.0 million. In addition, the Company is entitled to receive tiered royalties in the low to mid-single digits on product sales. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on GSK’s performance.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Zymeworks's research milestone — research and development collaborations (note 11)?
- Zymeworks (ZYME) reported research milestone — research and development collaborations (note 11) of $8.75M in Q4 2025.
- What does research milestone — research and development collaborations (note 11) mean?
- This metric represents revenue recognized from research and development collaboration agreements, including milestone payments, upfront fees, and research funding. It reflects the company's ability to monetize its proprietary technology platforms and drug discovery engine through strategic partnerships with other biopharmaceutical entities. This revenue stream is a critical indicator of the commercial validation of the company's research capabilities and its success in advancing pipeline assets through collaborative development.
Ask your AI about Zymeworks's research milestone — research and development collaborations (note 11).
Connect your AI assistant and compare segments, right in your chat.
